inspirator schreef op 11 januari 2017 19:58:
[...]
Exact Sciences has healthy results
Finally, Exact Sciences gained 19%. The maker of the Cologuard colon-cancer screening test gave preliminary fourth-quarter results, predicting that it would report sales of between $34.9 million and $35.4 million. That would be up more than 140% from year-ago levels, and Exact Sciences said it performed about 82,000 Cologuard tests during the quarter, more than double what it did during the same period in 2015. Progress in getting new healthcare providers and insurance companies to embrace the test had Exact Sciences CEO Kevin Conroy proclaiming that, "Cologuard is becoming a standard of care for 80 million Americans who should be screened for colon cancer." Final results won't be available until February, but investors are convinced that Exact Sciences is on exactly the right path toward success.
Read more:
www.fool.com/investing/2017/01/09/why...